Australia markets open in 2 hours 46 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
24.95+0.25 (+1.01%)
At close: 04:00PM EDT
24.90 -0.05 (-0.20%)
After hours: 04:38PM EDT

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
https://www.corcept.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees238

Key executives

NameTitlePayExercisedYear born
Dr. Joseph K. Belanoff M.D.Co-Founder, Pres, CEO & Director1.69M18.91M1957
Mr. Atabak MokariCFO & Treasurer687.98kN/A1977
Dr. Hazel Hunt Ph.D.Chief Scientific Officer826.67k885k1960
Mr. Sean MaduckPres of Corcept Endocrinology828.83k2.31M1977
Mr. Gary Charles RobbChief Bus. Officer & Sec.900.08k14.25M1963
Mr. Joseph Douglas LyonChief Accounting OfficerN/AN/A1979
Ms. Amy FloodChief HR & Communications OfficerN/AN/AN/A
Dr. William Guyer Pharm.D.Chief Devel. OfficerN/AN/A1968
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corporate governance

Corcept Therapeutics Incorporated’s ISS governance QualityScore as of 1 September 2022 is 7. The pillar scores are Audit: 10; Board: 4; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.